<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/929B1EF0-7686-456A-8318-1B529113EC65"><gtr:id>929B1EF0-7686-456A-8318-1B529113EC65</gtr:id><gtr:name>Genefirst Limited</gtr:name><gtr:address><gtr:line1>BUILDING E5 , CULHAM SCIENCE CENTRE</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 3DB</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/929B1EF0-7686-456A-8318-1B529113EC65" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>929B1EF0-7686-456A-8318-1B529113EC65</gtr:id><gtr:name>Genefirst Limited</gtr:name><gtr:address><gtr:line1>BUILDING E5 , CULHAM SCIENCE CENTRE</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 3DB</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>479197.0</gtr:offerGrant><gtr:projectCost>798662.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>122479.0</gtr:offerGrant><gtr:projectCost>122479.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2EFD27F0-5271-4DDB-8467-83F00159CD34"><gtr:id>2EFD27F0-5271-4DDB-8467-83F00159CD34</gtr:id><gtr:firstName>Guoliang</gtr:firstName><gtr:surname>Fu</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101759"><gtr:id>CE551E3F-76DB-4FD1-A417-FA492DC8298C</gtr:id><gtr:title>Finalise the development of a novel HPV test technology through clinical study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101759</gtr:grantReference><gtr:abstractText>Human papillomavirus (HPV) is one of the most common sexually transmitted infections (STI). Some, but not all, types of HPV can cause cervical cancer (high-risk HPV types, HR-HPV). Since early stage cervical carcinomas are nearly 100% curable, early detection is very important. Accurate molecular diagnosis is needed to inform patient management and follow-up treatment. However, current methods suffer from sub-optimal sensitivity, discrimination and/or complex hybridisation-based procedures. GeneFirst has developed a unique technology (Multiplex Probe Amplification) for sensitive type-specific detection of more than 15 targets (e.g. HR-HPV types) in a single closed tube reaction. In this project, we set out to analyse the clinical performance of this novel HPV molecular diagnostics test to identify patients who have HR-HPV. Such an assay would offer physicians better means to identify women at risk and optimise treatment strategies.</gtr:abstractText><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>601676</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101759</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>